The overexpression of epidermal growth factor receptor (EGFR) in more than 90% of HNSCC patients led to the approval of cetuximab (Erbitux), a monoclonal antibody targeting EGFR, in combination with radiation therapy for advanced local/regional carcinoma. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.